# A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients

> **NCT00862979** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 162 (actual)

## Conditions studied

- Heart Transplantation

## Interventions

- **DRUG:** Everolimus (EVR)
- **DRUG:** cyclosporine A (CyA)
- **DRUG:** tacrolimus (TAC)
- **DRUG:** Enteric coated mycophenolate sodium (EC-MPS)
- **DRUG:** mycophenolate mofetil (MMF)
- **DRUG:** Corticosteroids

## Key facts

- **NCT ID:** NCT00862979
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02-24
- **Primary completion:** 2017-03-06
- **Final completion:** 2017-03-06
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2018-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00862979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00862979, "A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00862979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*